Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00813098 · ClinicalTrials.gov registry record · Phase 2
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
A Phase 2 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT00813098: Completed Phase 2 study, sponsored by Lexicon Pharmaceuticals.
NCT00813098 is a Phase 2 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 155 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00813098, a Phase 2 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
Primary Outcome
The primary efficacy endpoint was the proportion of subjects experiencing relief of IBS pain and discomfort at Week 4 as measured by the response to the question,"In the past 7 days have you had adequate relief of your irritable bowel syndrome pain and discomfort?"
Interventions
- DRUG Placebo
- DRUG LX1031 High Dose
- DRUG LX1031 Low Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
What the finished NCT00813098 record still lists
NCT00813098 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00813098 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00813098 about?
NCT00813098 is a clinical study titled "Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome". The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
What is the current status of trial NCT00813098?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2008-12. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00813098?
The interventions under investigation include: Placebo (DRUG), LX1031 High Dose (DRUG), LX1031 Low Dose (DRUG).
Who is sponsoring clinical trial NCT00813098?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00813098's enrollment target sits among peer trials
155 448th of 2000 higher than 1,553 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia